Artem Oganesyan, Resident Physician at Jefferson Abington Hospital, shared a post on LinkedIn about a paper published in Clinical Lymphoma, Myeloma and Leukemia:
“Our meta-analysis of RCTs is presented at SOHO2025.
We showed clinical efficacy and safety of Pembrolizumab or Nivolumab (two most commonly used PD-1 inhibitors) for frontline treatment of classical Hodgkin Lymphoma in patients with advanced disease or unfit for standard treatment (chemotherapy).
Thank you Society of Hematologic Oncology for selecting our work for the Young Investigator Award.”
Title: HL-850: Clinical Efficacy and Safety of Pembrolizumab and Nivolumab in Frontline Treatment for Classical Hodgkin Lymphoma: A Systematic Review and Meta-Analysis
Authors: Artem Oganesyan, Andrew Gregory, Mark Gregory, Vahe Khachatryan, Liana Hayrapetyan, Deivid Badalian, Abhay Aradya, Aheed Javaid, Yervand Hakobyan
Read the full article.
More posts featuring Artem Oganesyan on OncoDaily.